Immunovant Inc.

IMVT

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Baker Bros. Advisors Perceptive Advisors RTW Investments

Catalysts

No catalysts tracked.

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 5,457,881Value: $138.7M

## Signal Note: Baker Bros. Initiates Large Position in Immunovant (IMVT) Baker Bros. built a substantial new position in Immunovant, a clinical-stage company developing batoclimab (anti-FcRn antibody) across autoimmune indications including myasthenia gravis, CIDP, thyroid eye disease, and warm autoimmune hemolytic anemia. **Note: The reported position value (~$138.7B) appears to be a data error — at recent share prices (~$25-30), 5.46M shares would be worth approximately $140-165M, which is still a meaningful conviction bet from the most concentrated biotech fund in the space.** Baker's entry is notable given upcoming Phase 3 readouts for batoclimab in MG and other indications expected in 2025, and their track record of building positions ahead of pivotal

Perceptive AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CNTA3 funds IRON3 funds SYRE3 funds CELC3 funds IMTX3 funds KOD3 funds KYMR3 funds AAVXF

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Perceptive Initiates $50.7M Position in Immunovant Edelman's entry into IMVT signals confidence in the company's lead asset, batoclimab (anti-FcRn monoclonal antibody), ahead of potential regulatory catalysts in autoimmune indications where FcRn inhibition has shown clinical promise. The $50.7M position size (notable for Perceptive) suggests conviction around near-term data readouts or approval timelines, likely in myasthenia gravis or IgG-mediated autoimmune conditions where FcRn mechanisms have demonstrated efficacy. Key to watch: Phase 3 results and FDA interactions for batoclimab's path to commercialization in a competitive but validated target space.